Drug Profile
Histamine glutarimide - EURRUS Biotech
Alternative Names: XC-8Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Unknown
- Developer EURRUS BIOTECH; Pharmenterprises; Valenta Pharmaceuticals
- Class Antiasthmatics; Antibronchitics; Biogenic amines; Peptides; Small molecules
- Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cough
- Phase II/III Respiratory tract infections
- Phase II Asthma
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Russia (PO, Tablet)
- 22 Aug 2022 Valenta Pharm initiates enrolment in a clinical trial (In volunteers) in Russia (PO, tablet) (NCT05558462)
- 29 Jul 2022 Valenta Pharm JSC completes phase-III clinical trials in Cough in Russia (PO) (NCT05273619)